What are the adverse effects of Farxiga (dapagliflozin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Adverse Effects of Farxiga (Dapagliflozin)

Farxiga (dapagliflozin) commonly causes genital mycotic infections, urinary tract infections, and volume depletion-related side effects, while more serious but rare complications include diabetic ketoacidosis and necrotizing fasciitis of the perineum. 1, 2

Common Adverse Effects

Genitourinary Effects

  • Genital mycotic infections: Most common side effect, particularly in women 1, 2
  • Urinary tract infections: Can be serious and potentially lead to hospitalization 2
  • Increased urination: Due to osmotic diuresis mechanism 1

Volume-Related Effects

  • Volume depletion: Manifesting as dizziness, orthostatic hypotension, dehydration 1
  • Hypotension: Particularly in elderly patients or those on diuretics 1
  • Initial eGFR decline: Typically 3-5 mL/min/1.73m² decrease that generally returns to baseline 3

Other Common Effects

  • Stuffy or runny nose and sore throat 2
  • Weight loss: Generally considered beneficial but can be significant 1
  • Elevated LDL cholesterol: May require monitoring 1

Serious Adverse Effects

Metabolic Complications

  • Diabetic ketoacidosis (DKA): Can occur with normal or only mildly elevated blood glucose ("euglycemic DKA") 3
    • Risk factors: Intercurrent illness, reduced food/fluid intake, reduced insulin doses, alcohol consumption
    • Requires immediate medical attention

Infectious Complications

  • Necrotizing fasciitis of the perineum (Fournier's gangrene): Rare but serious bacterial infection 2
    • Symptoms: Fever, weakness, pain/tenderness/swelling/redness in the genital/anal area
    • May require hospitalization, multiple surgeries, and can be life-threatening

Hypoglycemia

  • Low risk when used alone but increased risk when combined with insulin or sulfonylureas 2, 4
  • Symptoms include headache, confusion, hunger, shaking, drowsiness, dizziness, fast heartbeat

Renal Effects

  • Acute kidney injury: Risk increases with volume depletion 1
  • Not recommended in patients with eGFR <30 mL/min/1.73m² 3, 2

Allergic Reactions

  • Serious allergic reactions: Require immediate discontinuation and medical attention 2

Special Population Considerations

Elderly Patients

  • Higher risk of volume depletion, hypotension, and renal adverse events 1
  • Require closer monitoring

Renal Impairment

  • Reduced glycemic efficacy with declining renal function 1
  • Not recommended if eGFR <30 mL/min/1.73m² 3, 2

Precautions and Management

For Volume Depletion

  • Ensure adequate fluid intake
  • Consider temporary dose reduction in vulnerable patients
  • Monitor blood pressure and renal function

For Genital Mycotic Infections

  • Over-the-counter antifungal medications may help
  • Seek medical attention if symptoms persist

For DKA Prevention

  • Temporarily stop medication during illness, surgery, or prolonged fasting 1
  • Monitor for symptoms even with normal blood glucose levels

For Procedures

  • Discontinue dapagliflozin 3 days before elective or anticipated invasive procedures 3

Monitoring Recommendations

  • Regular assessment of renal function
  • Monitor for signs of volume depletion
  • Watch for symptoms of genital or urinary tract infections
  • Monitor LDL cholesterol levels

Despite these adverse effects, dapagliflozin has demonstrated significant cardiovascular and renal benefits in clinical trials, including reduced risk of heart failure hospitalization and cardiovascular death 3, 5, which should be considered when evaluating its overall risk-benefit profile.

References

Guideline

Dapagliflozin Side Effects and Precautions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Dapagliflozin in Patients with Chronic Kidney Disease.

The New England journal of medicine, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.